ライフサイエンスコーパス: kanamycin

1 typhi) to antibiotics such as ampicillin and kanamycin.

2 comparable to that of commercially available kanamycin.

3 to a reporter gene conferring resistance to kanamycin.

4 ive selection for resistance to bleomycin or kanamycin.

5 to a reporter gene conferring resistance to kanamycin.

6 sosomes in hair cells that were treated with kanamycin.

7 gB promoter were resistant to high levels of kanamycin.

8 from its native promoter were susceptible to kanamycin.

9 d in Escherichia coli by their resistance to kanamycin.

10 uce recombination and so remain resistant to kanamycin.

11 The strain was resistant to isoniazid and kanamycin.

12 formants and germinated on medium containing kanamycin.

13 or and carries a gene encoding resistance to kanamycin.

14 pC expression confers adaptive resistance to kanamycin.

15 ikacin, 99.2% for capreomycin, and 96.4% for kanamycin.

16 ncreased resistance against streptomycin and kanamycin.

17 mutagenesis and bacterial growth assays with kanamycin.

18 ll enhanced structural stability to APH than kanamycin.

19 5 to 2 mug/ml), amikacin (0.25 to 2 mug/ml), kanamycin (0.25 to 2 mug/ml), capreomycin (0.5 to 4 mug/

20 After unilateral intracochlear injections of kanamycin (1 and 2 weeks), VGLUT1 immunoreactivity (ir)

21 y blocked at 37 degrees C in the presence of kanamycin (100 microgram/ml) or chloramphenicol (200 mic

22 ceftiofur (49%) and, to a lesser extent, to kanamycin (19%), trimethoprim-sulfamethoxazole (17%), an

23 e promoter mutations conferred resistance to kanamycin [5 microg/mL < minimum inhibitory concentratio

24 eotide hairpin library that bind 6'-acylated kanamycin A (1) and 6'-acylated neamine (2) identified b

25 ion by modularly assembling 6'-N-5-hexyonate kanamycin A (K) onto a peptoid backbone.

26 stance to the aminoglycoside (AG) antibiotic kanamycin A (KAN) in Mycobacterium tuberculosis.

27 ucts formed are 4'-(adenosine-5'-phosphoryl)-kanamycin A and 4'-(m-nitrobenzyl phosphoryl)-kanamycin

28 ining 2'-amino substituents, also acetylated kanamycin A and amikacin that contain a 2'-hydroxyl subs

29 t multiamine-containing glycosides including kanamycin A and B, tobramycin, paromomycin, and neomycin

30 Conformations of kanamycin A and ribostamycin were compared to those of o

31 Bound conformations of kanamycin A and ribostamycin, in the active site of the

32 t acetylation takes place on the 6'-amine of kanamycin A and the adenylation on 3''- and 9-hydroxyl g

33 owing unique trends: 5'UNNNC3' loops for the kanamycin A derivative (where N is any nucleotide); 5'UN

34 erivative, and pyrimidine-rich loops for the kanamycin A derivative.

35 the divergent synthesis of three classes of kanamycin A derivatives.

36 a concentration range from 100pM to 1muM and kanamycin A from 10nM to 1mM.

37 B, the derivatives based upon tobramycin and kanamycin A have slightly lower RRE affinities, but bett

38 agnetic resonance analysis of the product of kanamycin A phosphorylation revealed that modification o

39 ons as the acetyltransferase responsible for kanamycin A resistance, a hallmark of extensively drug-r

40 Surprisingly, binding of gentamicin and kanamycin A to the chemically synthesized terminal hairp

41 ied products of both reactions revealed that kanamycin A was modified only at one position.

42 Two conformers of kanamycin A were matched well with the two conformers of

43 lyzed by kanamycin nucleotidyltransferase of kanamycin A with either ATP or m-nitrobenzyl triphosphat

44 nucleotidyltransferase catalyzed reaction of kanamycin A with m-nitrobenzyl triphosphate is 2 orders

45 For three of the aminoglycosides, 6''-azido-kanamycin A, 5-O-(2-azidoethyl)-neamine, and 6''-azido-t

46 uation of derivatives based upon neomycin B, kanamycin A, and tobramycin conjugates of 9-aminoacridin

47 Antibiotic substrates for AAC include kanamycin A, kanamycin B, tobramycin, sisomicin, neomyci

48 Gram-negative APH(3') types Ia and IIa with kanamycin A, neamine, and their respective difluorinated

49 o, binary, and ternary complexes of APH with kanamycin A, neomycin B, and metal-nucleotide.

50 ptamer probes with affinity to ampicillin or kanamycin A, respectively.

51 '' and/or O-6'' positions on the ring III of kanamycin A, show very strong activity as antifungal age

52 f RNA hairpin loops that bind derivatives of kanamycin A, tobramycin, neamine, and neomycin B via two

53 However, kanamycin A, which has a 2'-OH, shows a much smaller dec

54 ives of neomycin B, neamine, tobramycin, and kanamycin A.

55 n the nanomolar range for all substrates but kanamycin A.

56 formers were determined for the enzyme-bound kanamycin A.

57 ucture of the enzyme with bound MgAMPCPP and kanamycin A.

58 es or disappears as compared to the original kanamycin A.

59 anamycin A and 4'-(m-nitrobenzyl phosphoryl)-kanamycin A.

60 unambiguously assigned to the 4' hydroxyl of kanamycin A; thus, the products formed are 4'-(adenosine

61 ted with the htk gene encoding a heat-stable kanamycin adenyltransferase.

62 cumulate in vesicles 27 h after the start of kanamycin administration.

63 ies, including antibiotics of ampicillin and kanamycin, alcohols of ethanol and n-butanol and heavy m

64 biotics, including gentamicin, streptomycin, kanamycin, amikacin, and paromomycin, have no effect on

65 sed, a cleavable conjugate of the antibiotic kanamycin and a nonmembrane lytic, broad-spectrum antimi

66 The aminoglycosides kanamycin and amikacin are important bactericidal drugs

67 esistant to kanamycin and those resistant to kanamycin and amikacin.

68 ctive, whilst AMR bacteria to carbenicillin, kanamycin and both two antibiotics were 35 +/- 5%, 28 +/

69 In this report, we examined the effects of kanamycin and chloramphenicol, inhibitors of protein syn

70 3, on guinea pig ears deafened systemically (kanamycin and furosemide) or locally (neomycin).

71 The event recovery rates for nptII/kanamycin and hpt/hygromycin systems were 2.88 and 2.47%

72 llin), quinolone (enoxacin), aminoglycoside (kanamycin and neomycin), and polykeptide (tetracycline)

73 Transductants are selected with kanamycin and screened for loss of the mutant phenotype

74 nation with an allele of oppD interrupted by kanamycin and streptomycin resistance markers.

75 For kanamycin and streptomycin, molecular DST significantly

76 aminoglycosides streptomycin, amikacin, and kanamycin and the cyclic polypeptide capreomycin are all

77 BALB /c.D2(NrampG169) mice were treated with kanamycin and then infected with wild-type or mutant Sal

78 ions should distinguish strains resistant to kanamycin and those resistant to kanamycin and amikacin.

79 system to deliver both a selectable marker (kanamycin) and an Escherichia coli plasmid origin of rep

80 ble markers (ampicillin, chloramphenicol, or kanamycin), and a single FRT site.

81 nce to phage infection and to the antibiotic kanamycin, and an inability to form biofilms.

82 taining lethal concentrations of rifampicin, kanamycin, and nalidixic acid.

83 how that aminoglycoside antibiotics, such as kanamycin, and polyamines impinge upon this circuit.

84 cadmium, bacitracin, macrolides, penicillin, kanamycin, and streptothricin, although all isolates wer

85 the MICs of amikacin, gentamicin, neomycin, kanamycin, and tobramycin by a factor of two to eight, a

86 e, we summarized optical and electrochemical kanamycin aptasensors and focuses on recent advances and

87 detection and quantitative determination of kanamycin are needed.

88 we report the design and synthesis of seven kanamycin B (KANB) derivatives.

89 cheme inspired the synthesis of a library of kanamycin B analogues alkylated at various hydroxyl grou

90 the synthesis and antibacterial assay of new kanamycin B analogues.

91 3-, and 2'-amino groups of both neomycin and kanamycin B as being critical functionalities for bindin

92 Neomycin B and kanamycin B bind to pre-tRNAAsp with a Kd value that is

93 s residue partially restoring sensitivity to kanamycin B but not to neomycin.

94 t of an octyl group at the O-4'' position of kanamycin B converts this antibacterial aminoglycoside i

95 ubstituted 2-deoxystreptamine aminoglycoside kanamycin B led to improved selectivity for inhibition o

96 nd that the 3''-NH2 and 6''-OH groups of the kanamycin B parent molecule are not essential for antifu

97 Landscape analysis reveals that kanamycin B stabilizes a non-native, idiosyncratic confo

98 residue is more important for recognition of kanamycin B than neomycin, with mutation of this residue

99 the aminoglycoside antibiotics neomycin and kanamycin B to APH(3')-IIIa (an antibiotic phosphorylati

100 ydroxyl group replacing the 3''-NH2 group of kanamycin B was synthesized.

101 otic substrates for AAC include kanamycin A, kanamycin B, tobramycin, sisomicin, neomycin B, paromomy

102 restores sensitivity to neomycin but not to kanamycin B, with the origins of this differential effec

103 ach, 20 small libraries comprising 100 novel kanamycin-B derivatives have been prepared and evaluated

104 ity of ANT(2'') to confer resistance against kanamycins but not neomycins.

105 e of reviving clinically obsolete drugs like kanamycin by simple chemical modification and an alterna

106 valuated during a repeated administration of kanamycin by two methods.

107 ifampin, streptomycin, ethambutol, amikacin, kanamycin, capreomycin, ofloxacin, moxifloxacin, ethiona

108 ifampin, ethambutol, streptomycin, amikacin, kanamycin, capreomycin, ofloxacin, moxifloxacin, ethiona

109 the organism was disrupted by insertion of a kanamycin cassette by homologous recombination.

110 ding the second ORF by insertion of an Omega kanamycin cassette, and isogenic strains were constructe

111 h the alo gene was deleted and replaced by a kanamycin cassette, secreted barely detectable hemolytic

112 hleomycin, bleomycin, capreomycin, amikacin, kanamycin, cetylpyridinium chloride, and several sulfa d

113 rt to optimize the antibacterial activity of kanamycin class aminoglycoside antibiotics, we have acco

114 new strategy for structural modifications of kanamycin class aminoglycosides is suggested.

115 aled a break at 30 degrees C only in the APH-kanamycin complex in spectra collected between 21 degree

116 reak at 30 degrees C was observed in the APH-kanamycin complex yielding DeltaCp values of -0.7 kcal x

117 TG) this strain, DH1 lackan , cannot grow on kanamycin-containing media due to the repression of kan

118 ession and to further test lines selected on kanamycin-containing medium.

119 These new amphiphilic kanamycin derivatives bearing alkyl chains length of 4,

120 The antibacterial effect of the synthesized kanamycin derivatives declines or disappears as compared

121 es and modern techniques in aptasensor-based kanamycin detection techniques in order to provide reade

122 erial flora was manipulated, the addition of kanamycin did not affect the survival of Ent.

123 lycoside antibiotics, such as gentamicin and kanamycin, directly target the ribosome, yet the mechani

124 tibody confirmed the temporal changes in the kanamycin distribution.

125 Pase-filled vesicles increased with repeated kanamycin doses.

126 DST for rifampin and kanamycin from sputum samples yielded results after 12 h

127 ors that use resistance to nourseothricin or kanamycin/G418 to select for propagation in prototrophic

128 he copA gene was disrupted by insertion of a kanamycin gene through homologous recombination.

129 tructed by insertional inactivation with the kanamycin gene.

130 ce were exposed to a mixture of antibiotics (kanamycin, gentamicin, colistin, metronidazole, and vanc

131 ng assay to how that streptomycin, neomycin, kanamycin, gentamycin, and hygromycin B trigger conforma

132 tes and in liquid media for aminoglycosides (kanamycin, gentamycin, sisomycin, amikacin, spectinomyci

133 Kinetic studies show that kanamycin group aminoglycosides have higher k(cat) value

134 and 10 y (rpoB D435G [rifampicin]; rrs 1400 [kanamycin]; gyrA A90V [ofloxacin]; 1995 [95% HPD: 1988-1

135 Aminoglycoside antibiotics, such as kanamycin, have ototoxic side effects, which often resul

136 al protein Eis responsible for resistance to kanamycin in a significant fraction of kanamycin-resista

137 ous techniques have been developed to detect kanamycin in biological samples.

138 usly used coumermycin A(1), erythromycin and kanamycin in these studies.

139 In rats deafened by daily kanamycin injections (from P8 to P16), surviving inner h

140 Rats were given daily kanamycin injections from P8 to P16 to destroy hair cell

141 This strain contains a kanamycin insertion element in the chromosomal copy of l

142 An isogenic strain bearing a kanamycin insertion in mtaR was attenuated for survival

143 tains both an in-frame deletion of cdh and a kanamycin insertion mutation in lpxH, covered by pKJB5.

144 Resistance to the aminoglycoside kanamycin is a hallmark of XDR-TB.

145 Resistance to amikacin (AMK) and kanamycin (KAN) in clinical Mycobacterium tuberculosis s

146 acin (MOX), ofloxacin (OFX), amikacin (AMK), kanamycin (KAN), and capreomycin (CAP) using MGIT 960 an

147 ron added resistance to gentamicin (Gen) and kanamycin (Kan).

148 oroquinolone (FQ) drugs, amikacin (AMK), and kanamycin (KAN).

149 omallei include genes encoding resistance to kanamycin (Km), gentamicin (Gm), and zeocin (Zeo); howev

150 lysosomes paralleled those in intracellular kanamycin levels.

151 Experiments that used a kanamycin-marked Stx2 prophage demonstrated that ciprofl

152 nsertional inactivation of ORF1 with a polar kanamycin marker completely abolished urease activity an

153 nical isolates determined to be resistant to kanamycin may not be cross-resistant to amikacin, as is

154 red by selection for spectinomycin (aadA) or kanamycin (neo) resistance genes.

155 Enoxacin, kanamycin, neomycin, and tetracycline show synergistic g

156 Kanamycin nucleotidyltransferase [ANT (4',4' ')-I] from

157 The kanamycin nucleotidyltransferase catalyzed reaction of k

158 tate structure for the reaction catalyzed by kanamycin nucleotidyltransferase has been determined fro

159 egiospecificity of the reaction catalyzed by kanamycin nucleotidyltransferase of kanamycin A with eit

160 glutamine synthetase adenylyltransferase or kanamycin nucleotidyltransferase, but provides the compl

161 nitrobenzyl triphosphate, a new substrate of kanamycin nucleotidyltransferase, is reported.

162 We also did this for isoniazid, kanamycin, ofloxacin, rifampicin, and streptomycin resis

163 ed FPs) in two different binary plasmids for kanamycin or glufosinate selection, respectively, to all

164 ors that confer resistance to the antibiotic kanamycin or the herbicide glufosinate have been used to

165 olone (OR, 3.99 [95% CI, 1.10 to 14.40]) and kanamycin (OR, 5.47 [95% CI, 1.64 to 18.24]) resistance

166 fluoroquinolone, and at least 1 of amikacin, kanamycin, or capreomycin based on drug susceptibility t

167 ion with mycobacteria by using RIVET, with a kanamycin preselection and a sucrose postselection.

168 esistance within artificial microbiota under kanamycin pressures.

169 diarrhea for Salmonella colitis, we infected kanamycin-pretreated interleukin 8R (IL-8R) mutant mice

170 active hpyIIRM cassette [containing a 1.4 kb kanamycin resistance (aphA) marker], whether such acquis

171 rless chloramphenicol resistance (Cm(r)) and kanamycin resistance (Km(r)) cassettes, respectively, th

172 gI fragment within lob-2A was deleted, and a kanamycin resistance (Km(r)) gene was inserted into this

173 A spontaneous kanamycin resistance and capreomycin resistance mutation

174 he inactivation of sll0088 by insertion of a kanamycin resistance cartridge in the primary C14S(PsaC)

175 The insertion of a kanamycin resistance cartridge into cbbL resulted in a p

176 e sacB gene of Bacillus subtilis cloned in a kanamycin resistance cartridge.

177 A kanamycin resistance cassette (Kan(r)) was inserted into

178 , and interruption of the cloned gene with a kanamycin resistance cassette eliminated the overexpress

179 ing sequence was removed and replaced with a kanamycin resistance cassette flanked by two res sites f

180 cells, and disruption of the oapA gene with kanamycin resistance cassette insertion resulted in a si

181 BBA74 was disrupted by the insertion of a kanamycin resistance cassette into the coding region.

182 Replacement of GSU1501 with a kanamycin resistance cassette produced a similarly defec

183 nC mutant generated by introducing an aphA-3 kanamycin resistance cassette produced CPS with no O-ace

184 An in-frame replacement of eptB with a kanamycin resistance cassette rendered E. coli WBB06 (bu

185 rferi B31 by replacing the BBK32 gene with a kanamycin resistance cassette through homologous recombi

186 strain Ec1a (O1:K1:H7) were replaced with a kanamycin resistance cassette to produce an oxyRS mutant

187 hromosome by homologous recombination with a kanamycin resistance cassette to produce mutant J45-100.

188 duce a GlnA-deficient mutant of H. pylori, a kanamycin resistance cassette was cloned into the Tth111

189 y of phiBB-1 to package and transduce DNA, a kanamycin resistance cassette was inserted into a cloned

190 Afterwards, the kanamycin resistance cassette was removed from each muta

191 of R. leguminosarum was created by placing a kanamycin resistance cassette within acpXL, the gene whi

192 g rifampin resistance) or a large insertion (kanamycin resistance cassette).

193 d by insertional inactivation of plcR by the kanamycin resistance cassette, aphA3.

194 r hypB (HypB:kan) have been interrupted by a kanamycin resistance cassette.

195 subcloned and mutagenized by insertion of a kanamycin resistance cassette.

196 ent strain was constructed by insertion of a kanamycin resistance determinant within the ureC gene vi

197 (encoded by ssrA), coupled with a multicopy kanamycin resistance determinant, suppressed both lon ph

198 nstructed in this gene by the insertion of a kanamycin resistance DNA cassette into the chromosome.

199 the corresponding gene was disrupted with a kanamycin resistance gene (aphA3) in H. pylori ATCC 4350

200 A kanamycin resistance gene (kan) was introduced into B. b

201 eliloti gltA gene was mutated by inserting a kanamycin resistance gene and then using homologous reco

202 train, E. coli O157:H7 W6-13, by inserting a kanamycin resistance gene cassette (kan) into wcaD and w

203 mutant, which was created by insertion of a kanamycin resistance gene cassette at the 5' region of i

204 e K8.1 open reading frame and insertion of a kanamycin resistance gene cassette within the K8.1 gene.

205 344 (SL1344 trxA), replacing the gene with a kanamycin resistance gene cassette.

206 ch either fimA or orf365 was replaced with a kanamycin resistance gene did not participate in type 2

207 tions of the transposon Tn5 or Tn3-nice or a kanamycin resistance gene in each of these genes abolish

208 The MDV US3 orthologue was replaced with a kanamycin resistance gene in the infectious bacterial ar

209 nalysis revealed there was an insertion of a kanamycin resistance gene in the lgt2 gene of D4, which

210 e vectors into a plasmid containing a mutant kanamycin resistance gene in vitro.

211 ted DBB25, was constructed by insertion of a kanamycin resistance gene into alcA, one of the genes es

212 d one of these fragments hybridized with the kanamycin resistance gene of the plasmid vector.

213 ucted loxP511 transposons contained either a kanamycin resistance gene or no marker.

214 disrupted in strain 81-176 by insertion of a kanamycin resistance gene through homologous recombinati

215 LEU2 genes and a transposon-derived neomycin/kanamycin resistance gene were successfully expressed fr

216 es a gC-negative deletion mutant harboring a kanamycin resistance gene, a markerless mutant with the

217 of pDMG21A, a pVT745 derivative containing a kanamycin resistance gene, displayed a structural rearra

218 pJGS84, a derivative of pAP1 containing a kanamycin resistance gene, was able to replicate in Esch

219 onstructed by replacing the mazG gene with a kanamycin resistance gene.

220 der gene (originally annotated yfgK) with a kanamycin resistance gene.

221 plasmids containing mariner transposons and kanamycin resistance genes expressible in B. burgdorferi

222 ssette was designed so that the luxABCDE and kanamycin resistance genes were linked to form a single

223 gulated expression for the LEU2 and neomycin/kanamycin resistance genes.

224 mined in this study that exhibited low-level kanamycin resistance harbored eis promoter mutations.

225 antify the static and dynamic composition of kanamycin resistance in artificial microbiota to evaluat

226 plication origin, the nptIII gene conferring kanamycin resistance in bacteria, both the right and lef

227 The kanamycin resistance marker allows efficient direct sele

228 laced in a binary plasmid vectorcontaining a kanamycin resistance marker and a cauliflower mosaic vir

229 nstructs of fbpA and fbpB disrupted with the kanamycin resistance marker OmegaKm and containing varyi

230 omposite transposons containing IS6110 and a kanamycin resistance marker were constructed.

231 These mutations restored high levels of kanamycin resistance not through an improvement in the p

232 Bioluminescence and kanamycin resistance only occur in a bacterial cell if t

233 with both approaches using attP vectors with kanamycin resistance or spectinomycin resistance as the

234 the ability of these heterodimers to confer kanamycin resistance to Escherichia coli cells was impai

235 hotransferase type II gene, which can confer kanamycin resistance to transgenic plants, represent an

236 The mutations R177S and V198E restored the kanamycin resistance to wild-type levels while maintaini

237 d a genetic selection for splicing-dependent kanamycin resistance with no significant bias when six a

238 model successfully predicted the dynamics of kanamycin resistance within artificial microbiota under

239 The transposon introduces both positive (kanamycin resistance) and negative (I-SceI recognition s

240 cillin resistance), aphA1-Iab (which encodes kanamycin resistance), strA and strB (which encode strep

241 rom pUC21 (ampicillin resistance) and pUK21 (kanamycin resistance).

242 The loxP sites flank npt, conferring kanamycin resistance, and sacB, which confers sensitivit

243 s to the stable phenotypes of tumorigenesis, kanamycin resistance, and stable beta-glucuronidase (GUS

244 ulting MS17 clone possessed erythromycin and kanamycin resistance, flat-wave morphology, and microsco

245 cation, and genes for rare transfer RNAs and kanamycin resistance.

246 utonomously replicating plasmid that confers kanamycin resistance.

247 hia coli-H. pylori shuttle vector conferring kanamycin resistance.

248 is, which increase its expression and confer kanamycin resistance.

249 Genetic analysis of the kanamycin-resistance (KanR) trait in >900 independent tr

250 Interruption of por by a kanamycin-resistance cartridge between the codons for M2

251 nsion, was interrupted by the insertion of a kanamycin-resistance cassette between the ferrochelatase

252 optional chloramphenicol-, tetracycline-, or kanamycin-resistance cassettes.

253 plants transformed with a vector containing kanamycin-resistance gene (npt) flanked by FRT sites, wh

254 nd negative selection markers, which are the Kanamycin-resistance gene, the sacB gene and temperature

255 When used in tandem with a kanamycin-resistance marker, the cassette was successful

256 that suffers mutations during acquisition of kanamycin-resistance results in an overwhelming majority

257 nce of AID and a genetic reversion assay for kanamycin-resistance to investigate the causes of multip

258 lementation of a B. burgdorferi B31 A3 BBK32 kanamycin-resistant (B31 A3 BBK32::Kan(r)) mutant, defic

259 ites were amplified by PCR and cloned into a kanamycin-resistant (Kan(r)) suicide vector.

260 In contrast, a fraction of kanamycin-resistant (Km(r)) and nalidixic acid-resistant

261 tted us to generate hundreds of erythromycin/kanamycin-resistant B. burgdorferi clones with each of t

262 previously described nonmotile, rod-shaped, kanamycin-resistant B. burgdorferi flaB::Km null mutant

263 DNA sequencing of several kanamycin-resistant clones generated with one of the sui

264 mediated by electroporation of pJM6 produced kanamycin-resistant clones that were not reactive with M

265 s that contained both lp25 and lp56; the few kanamycin-resistant colonies isolated did not contain pB

266 air activity, evidenced by the appearance of kanamycin-resistant colonies.

267 Six of the kanamycin-resistant isolates had a previously unidentifi

268 After 1 month, the mice were challenged with kanamycin-resistant M. avium 104.

269 ce to kanamycin in a significant fraction of kanamycin-resistant Mycobacterium tuberculosis clinical

270 posed to a 48 h microaerobic shock generated kanamycin-resistant papillae after only 6-14 days.

271 Under normal atmospheric conditions, kanamycin-resistant papillae appeared after only about 5

272 lambda phage transduction and selecting for kanamycin-resistant recombinants.

273 he ability to internalize subsequently added kanamycin-resistant strains of S. typhi or S. typhimuriu

274 After a dose of oral kanamycin, Salmonella-infected congenic BALB/c.D2(NrampG

275 nts were identified by PCR and compared with kanamycin-selected transformants from the same T(1) seed

276 is B surface antigen and a gene encoding the kanamycin selection marker.

277 lus sinicus by Agrobacterium rhizogenes with kanamycin selection.

278 erichia coli when a carbenicillin, but not a kanamycin, selection marker was used.

279 These kanamycin-sensitive mutants were used as recipients in f

280 eed, the observed 330% gain we observe for a kanamycin sensor is 2-fold greater than that seen on pla

281 resistance of host cells to the antibiotics kanamycin, spectinomycin, and nourseothricin.

282 terobacter cloacae (conferring resistance to kanamycin, spectinomycin, lincomycin, and gentamycin/sis

283 The second was resistance to ampicillin, kanamycin, streptomycin, sulfamethoxazole, and tetracycl

284 ant, with distinct resistance to ampicillin, kanamycin, streptomycin, sulfamethoxazole, and tetracycl

285 re able to monitor varying concentrations of kanamycin sulfate as low as ~100 picogram/L.

286 rast, the lowest detectable concentration of kanamycin sulfate on silicon without any metallic struct

287 d trace amounts of molecules of antibiotics (kanamycin sulfate) dispersed on metasurfaces with terahe

288 were grown at the permissive temperature on kanamycin-supplemented agar and subsequently prevented f

289 Single i.p. doses of gentamicin or kanamycin suppressed SOAEs below 2.6 kHz, while modulati

290 Kanamycin therapy may thus select for mutants with incre

291 solates harboring eis mutations, selected by kanamycin therapy, which may drive the expansion of stra

292 This approach allows kanamycin to enter mammalian cells as a conjugate linked

293 ollowing endocytotic uptake, we administered kanamycin to neonatal chicks for 1 or 5 days (400 mg/kg/

294 Binding of kanamycins to APH occurs with a larger negative DeltaH i

295 5 strain was mutagenized with a mini-Tn5 Km (kanamycin) transposon, and mutants were tested for the a

296 dators) and bacteria (competitors), and (ii) kanamycin treatment to reduce competition from indigenou

297 infection over 6 h and its regression after kanamycin treatment were visualized by whole-body imagin

298 The time of diffusion of kanamycin was closely related to the time of cell death,

299 is of immunogold staining revealed that: (1) kanamycin was primarily localized in vesicles beneath th

300 00 mg/kg/day) and determined the location of kanamycin within the hair cells at various time points u